Celldex Therapeutics (CLDX) Earning Somewhat Favorable Media Coverage, Analysis Shows
News articles about Celldex Therapeutics (NASDAQ:CLDX) have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 48.0073606803599 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern’s rankings:
- Celldex Therapeutics Inc (NASDAQ: CLDX) – Hot Stock to Track – Alpha Beta Stock (alphabetastock.com)
- Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up – Nasdaq (nasdaq.com)
- Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2017 (finance.yahoo.com)
- Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 (finance.yahoo.com)
- Leerink Swann Analysts Raise Earnings Estimates for Celldex Therapeutics, Inc. (CLDX) (americanbankingnews.com)
Several brokerages have weighed in on CLDX. HC Wainwright reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $9.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. ValuEngine lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Finally, Zacks Investment Research downgraded Celldex Therapeutics from a “buy” rating to a “sell” rating in a research note on Monday, July 17th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. Celldex Therapeutics presently has a consensus rating of “Hold” and an average price target of $6.31.
Shares of Celldex Therapeutics (CLDX) remained flat at $$2.73 during trading hours on Monday. 1,050,800 shares of the company were exchanged, compared to its average volume of 1,722,933. Celldex Therapeutics has a fifty-two week low of $2.20 and a fifty-two week high of $5.02.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The firm had revenue of $3.90 million during the quarter, compared to the consensus estimate of $1.30 million. During the same quarter in the prior year, the company earned ($0.29) EPS. The firm’s revenue for the quarter was up 77.3% compared to the same quarter last year. equities analysts forecast that Celldex Therapeutics will post -0.97 earnings per share for the current year.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.